rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David M. Mott

Director

Company insider

Files Form 4 as: Director, Novavax; Director and 10% owner, Ardelyx; Director and 10% owner, Mersana Therapeutics; Director and 10% owner, Adaptimmune Therapeutics; Director and 10% owner, Epizyme; Director, Enliven Therapeutics; 10% owner, Regulus Therapeutics; 10% owner, Galera Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
555
Buys
98
Sells
13
Bought
$403.2M
Sold
$142.9M
Companies
39
Companies where not an officer
38
First trade
23 Feb 2006
Last trade
20 Jun 2026
Last filed
23 Jun 2026

Companies traded

Where they are an officer
Medimmune Inc /deDirector, Officer · last 18 Jun 20070 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
NVAX NovavaxDirector · Biotechnology · last 20 Jun 20260 buys · 1 sell
ARDX ArdelyxDirector, 10% owner · Biotechnology · last 16 Jun 202617 buys · 0 sells
Mersana TherapeuticsDirector, 10% owner · Biotechnology · last 6 Jan 20263 buys · 0 sells
Adaptimmune TherapeuticsDirector, 10% owner · last 1 Jul 20248 buys · 0 sells
EpizymeDirector, 10% owner · last 12 Aug 20229 buys · 3 sells
ELVN Enliven TherapeuticsDirector · Biotechnology · last 2 Jun 20229 buys · 0 sells
Regulus Therapeutics10% owner · last 24 Dec 20191 buy · 0 sells
Galera Therapeutics10% owner · Biotechnology · last 12 Nov 20191 buy · 0 sells
MIRM Mirum Pharmaceuticals10% owner · Biotechnology · last 22 Jul 20191 buy · 0 sells
Genocea Biosciences10% owner · last 24 Jun 20192 buys · 0 sells
Nightstar TherapeuticsDirector, 10% owner · last 7 Jun 20190 buys · 0 sells
TRVI Trevi Therapeutics10% owner · Biotechnology · last 9 May 20191 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
02Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Jun 2026filed 23 Jun 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—18,880filing
20 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—18,880 at $0.00filing
20 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—18,880 at $0.00filing
20 Jun 2026filed 23 Jun 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—18,880filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—21,270 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—14,180 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—21,270 at $0.00filing
18 Jun 2026filed 23 Jun 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—14,180 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code A—20,282 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code A—26,455 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code A—39,715 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX Ardelyxoption or derivative · BiotechnologySEC FORM 4 Code A—39,715 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code A—20,282 at $0.00filing
16 Jun 2026filed 18 Jun 2026ARDX ArdelyxBiotechnologySEC FORM 4 Code A—26,455 at $0.00filing
20 Feb 2026filed 23 Feb 2026ARDX ArdelyxBiotechnologySEC FORM 4 Bought$1.9M333,333 at $5.84filing
20 Feb 2026filed 23 Feb 2026ARDX ArdelyxBiotechnologySEC FORM 4 Bought$1.9M333,333 at $5.84filing
6 Jan 2026filed 6 Jan 2026Mersana TherapeuticsBiotechnologySEC FORM 4 Code U—23,546filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—181filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,002filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—740filing

The newest 500 lines are listed; the numbers count every line.

Sectors

Health Care33
Technology2
Not placed76

Buys in green, sells in red, by the company’s sector.

Related people

Joana GoncalvesChief Medical Officer · Also traded ORKA in the last 90 days
Arjun AgarwalSenior Vice President, Finance · Also traded ORKA in the last 90 days
Matthew W. CalkinsCEO and President · Also traded APPN in the last 90 days
J. Scott GarlandDirector · Also traded ELVN in the last 90 days
Lawrence Otto KleinChief Executive Officer · Also traded ORKA in the last 90 days
Paul T. QuinlanGeneral Counsel · Also traded ORKA in the last 90 days
Benjamin HohlChief Financial Officer · Also traded ELVN in the last 90 days
Helen Louise CollinsChief Medical Officer · Also traded ELVN in the last 90 days